Tuesday, July 7, 2015

BioLight in DES diagnostic collaboration with Ora

BioLight in DES diagnostic collaboration with Ora

June 15, 2015 by · Leave a Comment 

Tweet BioLight Life Sciences Investments (OTCQX:BLGTY; TASE:BOLT) has expanded its relationship with Ora Inc., with the signing of a collaboration agreement to advance the clinical, regulatory and commercial development of BioLight’s TeaRx multi-parameter diagnostic test for dry eye syndrome (DES). BioLight and Ora will jointly fund the clinical study and other activities required to obtain […]

Ocular Therapeutix eyeing sustained drug delivery

Ocular Therapeutix eyeing sustained drug delivery

March 17, 2015 by · Leave a Comment 

Tweet Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic drugs to an entire course of therapy in as little as a single dose. “We have multiple late-stage product candidates based on our proven hydrogel technology platform, addressing the largest […]

TearLab 2014 revenue climbs 35%

TearLab 2014 revenue climbs 35%

March 12, 2015 by · Leave a Comment 

Tweet 2014 net revenue for TearLab (NASDAQ:TEAR; TSX:TLB) totalled $19.7-million, up 35% from $14.6-million in 2013. “2014 was a building year for us, with our primary focus being on improving the integration of the TearLab Osmolarity test into the daily routines of our customers,” CEO, Elias Vamvakas, said in a statement. “Moving into 2015, with an […]

TearLab, Dipexium and Joint in Feltl 2015 Top Idea List

TearLab, Dipexium and Joint in Feltl 2015 Top Idea List

January 5, 2015 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB), Dipexium Pharmaceuticals (NASDAQ:DPRX) and The Joint Corp. (NASDAQ:JYNT) were included in Feltl & Co.’s 2015 Top Idea List released today. Analyst Ben Haynor rates TearLab at “strong buy” with a price target of $5. The stock closed at $2.58 on Friday. TearLab has first-mover advantage in point-of-care diagnostics for dry eye […]

Julie Speed joins TearLab as VP global marketing

Julie Speed joins TearLab as VP global marketing

October 6, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has appointed Julie Speed to its senior management team as VP of global marketing. Her mandate will be leading global marketing functions for the complete TearLab portfolio, including its internal diagnostics product line and the OcuHub platform. Ms. Speed joins TearLab after 15 years of at Alcon Laboratories, where her previous […]

Study shows hyperosmolarity may impact cataract surgery planning

Study shows hyperosmolarity may impact cataract surgery planning

September 15, 2014 by · Leave a Comment 

Tweet Preliminary results of the TearLab (NASDAQ:TEAR; TSX:TLB) Cataract Study were presented today at the XXXIII Congress of the European Society of Cataract and Refractive Surgeons (ESCRS). The groundbreaking study evaluated the relationship of a hyperosmolar tear film on keratometry readings.  The study demonstrated that hyperosmolar patients demonstrated a wider variation in keratometry calculations between […]

TearLab reports interim results of DED prevalence study in UK

TearLab reports interim results of DED prevalence study in UK

September 4, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has reported interim results of a multi-center dry eye disease (DED) prevalence study being carried out in the UK at four National Health Service (NHS) hospitals.  The study compared the effectiveness of the TearLab Osmolarity test to other traditional methods of diagnosing DED. Conducted under the auspices of the UK’s National […]

TearLab to unveil second generation tear testing platform

TearLab to unveil second generation tear testing platform

August 14, 2014 by · Leave a Comment 

Tweet At its analyst and investor day on Sept. 23, TearLab (NASDAQ:TEAR; TSX:TLB) plans to cover its current business and growth strategies, international market opportunities recent R&D activities, including development of a second-generation point-of-care tear testing platform. On the second quarter conference call earlier this month, CEO Elias Vamvaskas said most of the research has been […]

TearLab Q2 revenue climbs 42%

TearLab Q2 revenue climbs 42%

August 7, 2014 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has reported second quarter revenue of $5-million, up 42% from $3.5-million in the year earlier quarter and an increase of 19% sequentially from $4.2-million in the 2014 first quarter. A net 171 TearLab Osmolarity systems were added to the company’s installed base in the second quarter. Of those, 126 systems were […]

Mati Therapeutics gets another U.S. patent

Mati Therapeutics gets another U.S. patent

June 30, 2014 by · Leave a Comment 

Tweet Closely held Mati Therapeutics has received a U.S. patent covering its novel punctal plug delivery system for treatment of ocular indications (PPDS), including certain features for retaining the punctal plug within the nasolacrimal system of the eye during drug elution. The patent is titled, “Nasolacrimal Drainage System Implants For Drug Therapy.” Mati is actively […]

Next Page »

Email Newsletters with Constant Contact
Google+